Video

Dr. Penson on Biomarkers of Response to PARP Inhibitors in Ovarian Cancer

Richard T. Penson, MD, MRCP, associate professor, Harvard Medical School, and clinical director, Medical Gynecologic Oncology, Medicine, Massachusetts General Hospital, discusses prospective biomarkers that may predict response to PARP inhibitors in advanced ovarian cancer.

Richard T. Penson, MD, MRCP, associate professor, Harvard Medical School, and clinical director, Medical Gynecologic Oncology, Medicine, Massachusetts General Hospital, discusses prospective biomarkers that may predict response to PARP inhibitors in advanced ovarian cancer.

One-third of BRCA mutations are somatic, says Penson. Because somatic mutations are not inherited, they are not as commonly tested for. However, there has been a steady uptick of tissue tests in addition to germline testing in the blood or saliva, adds Penson.

About half of high-grade serious endometrioid tumors harbor homologous recombination deficiency (HRD) which is another important marker to look for.

Lastly, the field is evaluating a new generation of assays that will identify optimal combination therapies, says Penson. Approximately 20% to 30% of patients who harbor a BRCA mutation will acquire a reversion mutation. As such, assays that can help determine a combination that has the potential to overcome this resistance will be important, concludes Penson.

Related Videos
Benjamin Besse, MD, PhD, director, clinical research, Gustave Roussy Institute; professor, medical oncology, Paris-Saclay University
Fred Saad, CQ, MD, FRCS, FCAHS
Eric Kumar Singhi, MD
Seth Wander, MD, PhD
Lillian L. Siu, MD, FRCPC
Marc Machaalani, MD
Mark Awad, MD, PhD, chief, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center
Rasha Cosman, BSc, MBBS, FRACP
Saad Z. Usmani, MD, MBA, FACP, FASCO
Nicholas P. McAndrew, MD, MSCE